Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome

Japanese Journal of Cancer Research

Volumn 93, Issue 9, 2002, Pages 1029-1036

  Kakimoto, Tsunayuki ^a   Hattori, Yutaka ^a   Okamoto, Shinichiro ^a   Sato, Norihide ^a   Kamata, Tamihiro ^a   Yamaguchi, Masaya ^a   Morita, Kunihiko ^a   Yamada, Taketo ^a   Takayama, Nobuyuki ^a   Uchida, Hideo ^a   Shimada, Naoki ^a   Tanigawara, Yusuke ^a   Ikeda, Yasuo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibroblast growth factor; Multiple myeloma; Neutropenia; Thalidomide; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; LYMPHOKINE; SIGNAL PEPTIDE; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN A; ANGIOGENIC FACTOR; GROWTH FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 8; M PROTEIN; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INHIBITION KINETICS; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SOMNOLENCE; TREATMENT OUTCOME;

ADULT; AGED; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036748453     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb02480.x     Document Type: Article

References (28)

1. Alexanian, R. and Dimopoulos, M. The treatment of multiple myeloma. N. Engl. J. Med., 330, 484-489 (1994).
2. Wada, M., Mizoguchi, H., Kuriya, S., Taguchi, H., Kawamura, T., Maekawa, I., Shimazaki, C., Sato, Y., Niho, Y., Miyazaki, T., Shibata, A., Kitani, T., Hamajima, N. and Ohno, R. and Japanese Co-operative Study Group for the Treatment of Multiple Myeloma. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon (ROAD-IN) and a randomized comparison of interferon maintenance in multiple myeloma: a co-operative study in Japan. Br. J. Haematol., 109, 805-814 (2000).
3. Harousseau, J. L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A. M., Bourhis, J. H., Caillot, D., Boasson, M., Abgrall, J. F., Facon, T., Linassier, C., Cahn, J. Y., Lamy, T., Troussard, X., Gratecos, N., Pignon, B., Auzanneau, G. and Bataille, R. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood, 85, 3077-3085 (1995).
4. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G., Rossi, J. F., Casassus, Ph., Maisonneuve, H., Facon, T., Ifrash, N., Payen, C. and Bataille, R. for the Intergroupe Francaise du Myeloma. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med., 335, 91-97 (1996).
5. Barlogie B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. and Tricot, G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 89. 789-793 (1997).
6. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer. J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. and Crowley, J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 55-65 (1999).
7. Tseng S., Pak, G., Washenik, K., Pomeranz, M. K. and Shupak, J. L. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol., 35, 969-979 (1996).
8. D'Amato, R. J., Loughnan, M. S., Flynn, E. and Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 91, 4082-4085. (1994).
9. Baidas, S. M., Winer, E. P., Fleming, G. F., Harris, L., Pluda J. M., Crawford, J. G., Yamauchi, H., Isaacs, C., Hanfelt, J., Tefft, M., Flockhart, D., Johnson, M. D., Hawkins, M. J., Lippman, M. E. and Hayes, D. F. Phase II evaluation of thalidomide in patients with metastic breast cancer. J. Clin. Oncol., 18, 2710-2717 (2000).
10. Fine, H. A., Figg, W. D., Jaeckle, K., Wen, P. Y., Kyritsis, A. P., Loeffler, J. S., Levin, V. A., Black, P. M., Kaplan, R., Pluda, J. M. and Yung, W. K. A. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade glioma. J. Clin. Oncol., 18, 708-715 (2000).
11. Gutheil, J. and Finucane, D. Thalidomide therapy in refractory solid tumour patients. Br. J. Haematol., 110, 754 (2000).
12. Vacca, A., Ribiatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., and Dommacco, F. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol., 87, 503-508 (1994).
13. Vacca A., Ribiatti, D., Roncali, L. and Dommacco, F. Angiogenesis in B-cell lymphoproliferative diseases. Biological and clinical studies. Leuk. Lymphoma, 20, 27-38 (1995).
14. Vacca A., Loreto, M. D., Ribiatti, D., Stefano, R. D., Gadaleta-Caldarola, G., Lodice, G. Caloro, D. and Dammacco, F. Bone marrow of patients with active myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am. J. Hematol., 50, 9-14 (1995).
15. Vacca, A., Ribiatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. and Dommacco, F., Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 3064-3073 (1999).
16. Sato, N., Hattori, Y., Du, W., Yamada, T., Kamata, T., Kakimoto, T., Okamoto, S., Kawamura, C., Kizaki, M., Shimata N., Ote, Y., Hata, J. and Ikeda, Y. Elevated level of plasma basic fibroblast growth factor in multiple myeloma. correlates with increased disease activity. Jpn. J. Cancer. Res., 93, 459-466 (2002).
17. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J. and Barlogie, B. Anti-tumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571 (1999).
18. Alexanian, R. and Weber, D. Thalidomide for resistant and relapsing myeloma. Semin. Hematol., 37, 22-25 (2000).
19. Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. and Malm, C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol., 109, 89-96 (2000).
20. Kneller, A., Raanani, P., Hardan, I., Avigdor, A., Levi, I., Berkowicz, M. and Ben-Bassat, I. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br. J. Haematol., 108, 391-393 (2000).
21. Gore, M. E., Selby, P. J. Viner C., Clark, P. I., Meldrum, M., Millar, B., Bell, J., Maitland, J. A., Milan, S., Judson, I.R., Zuiable, A., Tillyer, C., Slevin, M. and Malpas, J.S. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet, ii, 879-881 (1989).
22. Boughton, B.J., Sheehan, T. M. T., Wood, J., O'Brien, D., Butler, M., Simpson, A, and Hale, K. A. High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Ann. Clin. Biochem., 32, 79-83 (1995).
23. Durie, B. G. M. and Salmon, S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854 (1975).
24. Schreiber, S., Ackermann, J., Obermair, A., Kaufmann, H., Urbauer, E., Aletaha, K., Gisslinger, H., Chott, A., Huber, H. and Drach, J. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. Br. J. Haematol., 110, 605-609 (2000).
25. Larkin, M. Low-dose thalidomide seems to be effective in multiple myeloma. Lancet, 354, 925 (1999).
26. Osman, K., Comenzo, R. and Rajikumar, S.V. Deep vein thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med., 344, 1951-1952 (2001).
27. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y. T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., Muller, G., Stirling, D. I. and Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950 (2000).
28. Neben, K., Moehler, T., Egerer, G., Kraemer, A., Hillengass, J., Benner, A., Ho, A. D. and Goldschmidt, H. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7, 2675-2681 (2001).